Last update 01 Nov 2024

CXCR5 x EGFR

Last update 01 Nov 2024

Basic Info

Related Targets

CXCR5EGFR

Drugs associated with CXCR5 x EGFR

Autologous EGFR-CAR T cells(Sun Yat-Sen University)

Target

CXCR5 x EGFR

Mechanism

CXCR5 antagonists [+3]

Active Org.

Sun Yat-Sen University [+1]

Originator Org.

Sun Yat-Sen University

Active Indication

Non-Small Cell Lung Cancer

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with CXCR5 x EGFR

100 Translational Medicine associated with CXCR5 x EGFR

0 Patents (Medical) associated with CXCR5 x EGFR

Literatures (Medical) associated with CXCR5 x EGFR

01 Apr 2022·International Journal of Immunopathology and PharmacologyQ4 · MEDICINE

Elevated number of IL-21+ TFH and CD86+CD38+ B cells in blood of renal transplant recipients with AMR under conventional immuno-suppression

Q4 · MEDICINE

ArticleOA

Author: Tang, Tongyu ; Wang, Li ; Wang, Haifeng ; Qu, Zhihui ; Jiang, Yanfang ; Si, Rui ; Liu, Jing

The objective of this study is to detect the number of different subsets of TFH and B cells in renal transplant recipients (RTR) with antibody-mediated acute rejection (AMR), acute rejection (AR), chronic rejection (CR), or transplant stable (TS). The present study was a prospective study. The numbers of ICOS +, PD-1+ and IL-21+ TFH, CD86+, CD38+, CD27+, and IgD- B cells in 21 patients with end-stage renal disease (ESRD) and post-transplant times were measured by flow cytometry. The level of serum IL-21 was detected by ELISA. The numbers of circulating CD4+CXCR5+, CD4+CXCR5+ICOS+, CD4+CXCR5+PD-1+, CD4+CXCR5+IL-21+ TFH, CD19+CD86+, and CD19 +CD86+CD38+ B cells as well as the level of serum IL-21 in the AMR, AR, and CR groups at post-transplantation were significantly higher than those at pre-transplantation. In contrast, the number of circulating CD19+CD27+IgD B cells was significantly increased in the TS groups in respect to the other groups. Moreover, the numbers of circulating CD4+CXCR5+IL-21+ TFH cells, CD19+CD86+CD38+ B cells as well as the level of serum IL-21 were positive related to the level of serum Cr while showing negative correlated with the values of eGFR in the AMR groups at post-transplantation for 4 and 12 weeks. Circulating TFH cells may be a biomarker in RTR with AMR, which can promote the differentiation of B cells into plasma cells by activating B cells, thereby promoting disease progression.

01 Sep 2021·Molecular Therapy - OncolyticsQ2 · MEDICINE

CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

Q2 · MEDICINE

ArticleOA

Author: Mo, Wenjun ; Luo, Min ; Zheng, Yanfang ; Li, Guangchao ; Han, Zheping ; Qin, Lingyu ; Guo, Jintao ; Ding, Wen

The efficacy of chimeric antigen receptor (CAR) T is still not optimal for solid tumors, partly due to the lack of T cell infiltration to the tumor site. One promising strategy is to guide T cells through tumor-specific chemokines, provided that the matching chemokine receptors are expressed on T cells. Previous reports showed that, for non-small cell lung cancer (NSCLC) patients, the tumor sites express high levels of chemokine CXCL13, whereas CXCR5, the only receptor for CXCL13, is mainly expressed on B cells and follicle helper T cells. Therefore, we engineered an epidermal growth factor receptor (EGFR) CAR-T cell to express a second receptor CXCR5, to facilitate migration of CAR-T cells to the CXCL13-expressing NSCLC tumors, and to minimize EGFR-CAR-T possible off-tumor, on-target toxicity. We first confirmed CXCL13 expression in NSCLC patient blood and cancer tissues and the absence of CXCR5 expression in normal CD3 T cells. Next, we demonstrated that EGFR-CXCR5-CAR-T cells have similar killing activity as EGFR-CAR-T with a cytotoxicity assay in vitro. Furthermore, the in vitro Transwell assay and in vivo xenograft tumor mouse model were used to confirm that EGFR-CXCR5-CAR-T exhibits a significant increase in T cell infiltration to CXCL13-expressing tumors and eradicates the CXCL13-expressing tumors more efficiently.

01 Jan 2020·OncoImmunologyQ2 · MEDICINE

Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 ⁺ CD8 ⁺ T cell abundance

Q2 · MEDICINE

ArticleOA

Author: Zhou, Quan ; Huang, Qiuren ; Liu, Zhaopei ; Xia, Yu ; Zhu, Yu ; Zhang, Weijuan ; Wang, Zewei ; Zeng, Han ; Zhang, Hongyu ; Guo, Jianming ; Dai, Bo ; Xiong, Ying ; Liu, Li ; Chang, Yuan ; Wang, Jiajun ; Chen, Yifan ; Bai, Qi ; Xu, Le ; Qu, Yang ; Wang, Yiwei

Bladder cancer is the ninth most frequent-diagnosed disease worldwide, bearing high morbidity and mortality rates. Studies have shown that a particular population of CXCR5⁺CD8⁺ T cells was associated with superior prognosis in various tumor types, and yet its role in muscle-invasive bladder cancer (MIBC) remains unclear. In this study, 662 MIBC patients from 3 cohorts (Zhongshan Hospital, n = 141; Shanghai Cancer Center, n = 108; The Cancer Genome Atlas, n = 403) were analyzed retrospectively. 11 fresh resected samples of MIBC were examined to characterize the phenotype of CXCR5⁺CD8⁺ T cells and 402 MIBC patients from TCGA were applied for bioinformatics analysis. It was explored that the abundance of intratumoral CXCR5⁺CD8⁺ T cells indicated superior overall survival and disease-free survival. Patients with a higher infiltration of CXCR5⁺CD8⁺ T cells in tumor tissue benefit more from adjuvant chemotherapy (ACT). Intratumoral CXCR5⁺CD8⁺ T cells displayed cytolytic and self-renewal features. Remarkably, CXCR5⁺CD8⁺ T cells were mainly presented in the basal and stromal-rich subtypes of MIBC and tumors with enriched CXCR5⁺CD8⁺ T cells showed limited FGFR3 signaling signature and activated immunotherapeutic and EGFR associated pathway. In conclusion, we identified an excellent prognosis and ACT sensitive subtype of MIBC with intratumoral CXCR5⁺CD8⁺ T cell abundance. Tumors with high density of CXCR5⁺CD8⁺ T cells possessed potential sensitivity to immunotherapy and EGFR-targeted therapy. CXCR5⁺CD8⁺ T cells provide a new potential biomarker as well as a therapeutic target in MIBC.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis